Medoff G, Valeriote F, Dieckman J
J Natl Cancer Inst. 1981 Jul;67(1):131-5.
Amphotericin B (AmB) has been shown to potentiate the cytotoxicity of several different anticancer agents in AKR mice. The extent of potentiation, as assessed quantitatively by a spleen colony assay, varied from a factor of approximately 3 for 1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU) to over 100 for a number of alkylating agents and to over 1,000 for 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Most phase-specific agents showed little potentiation of cytotoxicity by AmB. A dose-response effect was noted with both BCNU and adriamycin, with increased potentiation being observed with increasing doses of the anticancer agents. The effect on increase in life-span was also studied and for most of the combinations it correlated with the potentiating effects disclosed by the spleen colony assay. Such a correlation was not found for AmB combined with either BCNU or vincristine.
两性霉素B(AmB)已被证明可增强几种不同抗癌药物对AKR小鼠的细胞毒性。通过脾集落试验定量评估,增强程度有所不同,1,3-双(2-氯乙基)-1-亚硝基脲(BCNU)约为3倍,多种烷基化剂超过100倍,1-(2-氯乙基)-3-环己基-1-亚硝基脲超过1000倍。大多数细胞周期特异性药物显示出两性霉素B对细胞毒性的增强作用很小。BCNU和阿霉素均呈现剂量反应效应,随着抗癌药物剂量增加,增强作用也增加。还研究了对寿命延长的影响,对于大多数组合,其与脾集落试验揭示的增强作用相关。两性霉素B与BCNU或长春新碱联合使用时未发现这种相关性。